BACKGROUND: The goal of this study was to determine whether antidonor antibodies directed against human leukocyte antigen (HLA) or endothelial cells (ECs) expressed antigens, including major histocompatibility complex class I chain-related antigens A (MICA) are associated with the diagnosis of antibody-mediated rejection (AMR) in heart transplant recipients. METHODS: We studied posttransplant antidonor HLA antibodies in 168 heart allograft recipients transplanted from October 2001 to December 2005. Among them, there were 37 AMR+ patients and 131 age- and sex- matched AMR- controls. Sera were collected at the time of protocol biopsies and tested for the presence of HLA antibodies. Seventy-two of the 168 patients were genotyped for donor and recipient MICA alleles and were tested for the presence of anti-MICA antibodies. Thirty-one patients who never developed antibodies to HLA or MICA were further tested for anti-EC antibodies. RESULTS AND CONCLUSIONS: Of 37 AMR+ patients, 22 (60%) developed donor-specific antibodies (DSA) to HLA compared with 6 of 131(4%) AMR- patients (P<0.0001). Of the remaining 15 AMR+ patients, 5 had anti-HLA antibodies that were not donor specific and 10 did not show any HLA antibodies. In the subgroup of 72 patients, all 19 AMR+ patients had clearly demonstrable antibodies reactive with donor HLA, MICA or with nondonor-derived ECs, with 30% of them showed antibodies directed to non-HLA antigens. The incidence of transplant coronary artery disease was significantly higher in patients who had DSA to HLA and MICA compared with patients without DSA.
BACKGROUND: The goal of this study was to determine whether antidonor antibodies directed against human leukocyte antigen (HLA) or endothelial cells (ECs) expressed antigens, including major histocompatibility complex class I chain-related antigens A (MICA) are associated with the diagnosis of antibody-mediated rejection (AMR) in heart transplant recipients. METHODS: We studied posttransplant antidonor HLA antibodies in 168 heart allograft recipients transplanted from October 2001 to December 2005. Among them, there were 37 AMR+ patients and 131 age- and sex- matched AMR- controls. Sera were collected at the time of protocol biopsies and tested for the presence of HLA antibodies. Seventy-two of the 168 patients were genotyped for donor and recipient MICA alleles and were tested for the presence of anti-MICA antibodies. Thirty-one patients who never developed antibodies to HLA or MICA were further tested for anti-EC antibodies. RESULTS AND CONCLUSIONS: Of 37 AMR+ patients, 22 (60%) developed donor-specific antibodies (DSA) to HLA compared with 6 of 131(4%) AMR- patients (P<0.0001). Of the remaining 15 AMR+ patients, 5 had anti-HLA antibodies that were not donor specific and 10 did not show any HLA antibodies. In the subgroup of 72 patients, all 19 AMR+ patients had clearly demonstrable antibodies reactive with donor HLA, MICA or with nondonor-derived ECs, with 30% of them showed antibodies directed to non-HLA antigens. The incidence of transplant coronary artery disease was significantly higher in patients who had DSA to HLA and MICA compared with patients without DSA.
Authors: R Dechend; V Homuth; G Wallukat; J Kreuzer; J K Park; J Theuer; A Juepner; D C Gulba; N Mackman; H Haller; F C Luft Journal: Circulation Date: 2000-05-23 Impact factor: 29.690
Authors: J D Smith; V M Brunner; S Jigjidsuren; I M Hamour; A M McCormack; N R Banner; M L Rose Journal: Am J Transplant Date: 2009-06-26 Impact factor: 8.086
Authors: M Yeh; N Leitinger; R de Martin; N Onai; K Matsushima; D K Vora; J A Berliner; S T Reddy Journal: Arterioscler Thromb Vasc Biol Date: 2001-10 Impact factor: 8.311
Authors: S Jurcevic; M E Ainsworth; A Pomerance; J D Smith; D R Robinson; M J Dunn; M H Yacoub; M L Rose Journal: Transplantation Date: 2001-04-15 Impact factor: 4.939
Authors: Michael E Breimer; Lennart Rydberg; Annette M Jackson; Donna P Lucas; Andrea A Zachary; Joseph K Melancon; Jon Von Visger; Ronald Pelletier; Susan L Saidman; Winfred W Williams; Jan Holgersson; Gunnar Tydén; Göran K Klintmalm; Sonnya Coultrup; Suchitra Sumitran-Holgersson; Per Grufman Journal: Transplantation Date: 2009-02-27 Impact factor: 4.939
Authors: Julia D Wulfkuhle; Runa Speer; Mariaelena Pierobon; Julie Laird; Virginia Espina; Jianghong Deng; Enzo Mammano; Sherry X Yang; Sandra M Swain; Donato Nitti; Laura J Esserman; Claudio Belluco; Lance A Liotta; Emanuel F Petricoin Journal: J Proteome Res Date: 2008-02-08 Impact factor: 4.466
Authors: N M Valenzuela; L Hong; X-Da Shen; F Gao; S H Young; E Rozengurt; J W Kupiec-Weglinski; M C Fishbein; E F Reed Journal: Am J Transplant Date: 2012-12-27 Impact factor: 8.086
Authors: Matthew M DeNicola; Sam S Weigt; John A Belperio; Elaine F Reed; David J Ross; W Dean Wallace Journal: J Heart Lung Transplant Date: 2013-01-10 Impact factor: 10.247